Next Article in Journal
Recent Studies on Ponatinib in Cancers Other Than Chronic Myeloid Leukemia
Previous Article in Journal
A Systematic Review and Meta-Analysis Comparing Liver Resection with the Rf-Based Device Habib™-4X with the Clamp-Crush Technique
Open AccessReview

Novel Agents for Acute Myeloid Leukemia

1
Section of Hematology Department of Medical and Surgical Sciences, Azienda Ospedaliera Universitaria di Modena Università di Modena e Reggio Emilia, 41125 Modena, Italy
2
Division of Hematology and Bone Marrow Transplantation, Ospedali Riuniti Villa Sofia-Cervello, 90146 Palermo, Italy
3
Hematology and Transplant Center, Azienda Ospedaliera Marche Nord, 61121 Pesaro, Italy
4
Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori (IRST) IRCCS, 47014 Meldola (FC), Italy
5
Hematology, Department of Biomedicine and Prevention, “Tor Vergata” University of Rome, 00133 Roma, Italy
*
Author to whom correspondence should be addressed.
Cancers 2018, 10(11), 429; https://doi.org/10.3390/cancers10110429
Received: 1 October 2018 / Revised: 5 November 2018 / Accepted: 6 November 2018 / Published: 9 November 2018
Acute myeloid leukemia (AML) is a complex hematological disease characterized by genetic and clinical heterogeneity. Recent advances in the understanding of AML pathogenesis have paved the way for the development of new agents targeting specific molecules or mechanisms that contribute to finally move beyond the current standard of care, which is “3 + 7” regimen. In particular, new therapeutic options such as targeted therapies (midostaurin and enasidenib), monoclonal antibodies (gemtuzumab ozogamicin), and a novel liposomal formulation of cytarabine and daunorubicin (CPX-351) have been recently approved, and will be soon available for the treatment of adult patients with AML. In this review, we will present and describe these recently approved drugs as well as selected novel agents against AML that are currently under investigation, and show the most promising results as monotherapy or in combination with chemotherapy. The selection of these emerging treatments is based on the authors’ opinion. View Full-Text
Keywords: acute myeloid leukemia; “7 + 3” regimen; gemtuzumab ozogamicin; CPX-351; FLT3; midostaurin; enasidenib; palliative care acute myeloid leukemia; “7 + 3” regimen; gemtuzumab ozogamicin; CPX-351; FLT3; midostaurin; enasidenib; palliative care
Show Figures

Figure 1

MDPI and ACS Style

Luppi, M.; Fabbiano, F.; Visani, G.; Martinelli, G.; Venditti, A. Novel Agents for Acute Myeloid Leukemia. Cancers 2018, 10, 429.

Show more citation formats Show less citations formats
Note that from the first issue of 2016, MDPI journals use article numbers instead of page numbers. See further details here.

Article Access Map by Country/Region

1
Back to TopTop